Tejas Patil, MD

Professional Titles

• Assistant Professor

Recognitions

• IASLC John Fisher Young Investigator Award, International Association for Lung Cancer (IASLC) (2019)
  The objective of the IASLC Foundation John’s Legacy Fellowship Award is to fund highly innovative proposals for the early detection and screening of lung cancer.
• Hamoui Foundation / LUNGevity Clinical Research Award, Lungevity (2022)
  Central thesis of this proposal is to leverage more sophisticated laboratory techniques to better detect and define EGFR and MET resistance to targeted therapies and to utilize amivantamab, a bi-specific antibody to EGFR and MET, for patients who develop resistance to targeted therapies.
• Cancer League of Colorado Research Award, Cancer League of Colorado (2022)
  The central thesis of this proposal is that elevated tumor cell PD-L1 expression prevents productive cytotoxic T cell engagement driven by tumor cell-autonomous induction of an interferon response program mediated by ALK TKI treatment. We will explore various in vitro and in vivo models to understand the role of PDL1 expression as a biomarker to ALK TKI response.
• TORI Career Enhancement Award, Thoracic Oncology Research Initiative (2023)
  The objective of this proposal is to characterize MET receptor tyrosine kinase adaptations within drug-tolerant persister cells in non-small cell lung cancer (NSCLC) treated with oral tyrosine kinase inhibitors (TKIs)
• Gilead Research Scholars, Gilead (2023)
  The objective of this proposal is to use spatial multi-omics to characterize ligand and receptor tyrosine kinase adaptations within drug-tolerant persister cells in non-small cell lung cancer (NSCLC) treated with oral tyrosine kinase inhibitors (TKIs)
• Rising Star Award, University of Colorado School of Medicine (2024)
  The Rising Star Awards are given to early-career faculty members who exemplify the department’s core values of excellence in patient care, research, education, and community service.
• AB Nexus Research Award, AB Nexus Research Collaboration Grant Program (2024)
  The AB Nexus Award funds collaborative initiatives from investigators at CU Anschutz and CU Boulder. This proposal explores cell cycling adaptations in drug-tolerant persister cells in non-small cell lung cancer treated with tyrosine kinase inhibitors. My co-collaborator is Dr. Sabrina Spencer (Associate Professor, Department of Biochemistry, CU Boulder)
• Paul Calabresi Clinical Oncology Scholar, National Cancer Institute (NCI) (2024)
  The purpose of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO) NCI K12 is to increase the number of clinicians trained in clinical and translational cancer research, and to promote their career development as cancer researchers.

Research Interests

Publications

• Patil T, Pacheco JM, Dimou A, Purcell WT, Rossi C, Bunn PA, Doebele RC, Camidge DR, Ferrigno L. Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR -Mutant Non-small Cell Lung Cancer. Front Oncol. 2020;10:510. PubMed PMID: 32351892
• Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 May;21(3):e191-e204. PubMed PMID: 31859066
• Patil T, Smith DE, Bunn PA, Aisner DL, Le AT, Hancock M, Purcell WT, Bowles DW, Camidge DR, Doebele RC. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. J Thorac Oncol. 2018 Nov;13(11):1717-1726. PubMed PMID: 29981925
• Ziemke M, Patil T, Nolan K, Tippimanchai D, Malkoski SP. Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer. Lung Cancer. 2017 Jul;109:28-35. PubMed PMID: 28577946
• Patil T, Aisner DL, Noonan SA, Bunn PA, Purcell WT, Carr LL, Camidge DR, Doebele RC. Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status. Lung Cancer. 2016 Jun;96:27-32. PubMed PMID: 27133746
• Patil T, Mansoori J, Murphy R, Malkoski S. The answer is skin deep: a case of intravascular large B cell lymphoma presenting as progressive paresis and bilateral abducens nerve. Case Reports in Clinical Pathology. 2016. 3(3): DOI 10.5430/xyz.v1n1p1
• Iams WT, Yu H, Shyr Y, Patil T, Horn L, McCoach C, Kelly K, Doebele RC, Camidge DR. Heterogenous clinical syndromes existing within patients with Stage IV KRAS mutant non-small cell lung cancer. Presented at 2016 17th World Conference on Lung Cancer; Vienna, Austria
• Roberts PJ, He S, Schvartsman G, Patil T, Sorrentino JA, Bisi JE, Hoyer R, Schuster SR, Camidge DR, Strum JC, Heymach JV, Ferrarotto R, Sharpless NE, Malik RK. G1T28, a CDK4/6 Inhibitor, preserves T lymphocyte function from damage by cytotoxic chemotherapy. Presented at 2016 EORTC-NCI-AACR Symposium. Nov 2016, Munich, Germany.
• Hart LL, Roberts PJ, Ferrarotto R, Bordoni R, Conkling P, Patil T, Rocha-Lima CMS, Owonikoko TK, Schuster SR, Jotte R, Hoyer R, Stabler K, Makhuli KM, Aljuma R. G1T28, a cyclin dependent kinase 4/6 inhibitor, in combination with topotecan for previously treated small cell lung cancer (SCLC): preliminary results. Presented at 2016 17th World Conference on Lung Cancer; Vienna, Austria
• Patil T, Mushtaq R, Marsh S, Azelby C, Pujara M, Davies KD, Aisner DL, Purcell WT, Schenk EL, Pacheco JM, Bunn PA, Camidge DR, Doebele RC. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 May;21(3):e191-e204. PubMed PMID: 31859066
• Reckamp KL, Patil T, Kirtane K, Rich TA, Espenschied CR, Weipert CM, Raymond VM, Santana-Davila R, Doebele RC, Baik CS. Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis. Clin Lung Cancer. 2020 Nov;21(6):545-552.e1. PubMed PMID: 32665165
• Schenk EL, Patil T, Pacheco J, Bunn PA Jr. 2020 Innovation-Based Optimism for Lung Cancer Outcomes. Oncologist. 2020 Nov 11. [Epub ahead of print] PubMed PMID: 33179378
• Hararah MK, Stokes WA, Oweida A, Patil T, Amini A, Goddard J, Bowles DW, Karam SD. Epidemiology and treatment trends for primary tracheal squamous cell carcinoma. Laryngoscope. 2020 Feb;130(2):405-412. PubMed PMID: 30977524
• Johanna C. Bendell, Kian-Huat Lim, Mark E. Burkard, Jessica J. Lin, Young Kwang Chae, Mark A. Socinski, Gazala Khan, Karen L. Reckamp, Shawn Leland, Douglas Plessinger, Lori Kunkel, Efrat Dotan, Gregory Otterson, Sai-Hong Ignatius Ou, Tejas Patil, John V. Heymach, Edward S. Kim. CRESTONE – Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) Fusions – A phase 2 study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210) [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2020 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2020;80(22 Suppl):Abstract nr PO-003
• Noonan SA, Patil T, Gao D, King GG, Thibault JR, Lu X, Bunn PA, Doebele RC, Purcell WT, Barón AE, Camidge DR. Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol. 2018 Jan;13(1):134-138. PubMed PMID: 28843358
• Ng TL, Morgan RL, Patil T, Barón AE, Smith DE, Ross Camidge D. Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor. Lung Cancer. 2018 Dec;126:112-118. PubMed PMID: 30527174
• Ng TL, Liu Y, Dimou A, Patil T, Aisner DL, Dong Z, Jiang T, Su C, Wu C, Ren S, Zhou C, Camidge DR. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer. Cancer. 2019 Apr 1;125(7):1038-1049. PubMed PMID: 30548240
• Ng TL, Smith DE, Mushtaq R, Patil T, Dimou A, Yang S, Liu Q, Li X, Zhou C, Jones RT, Tu MM, Yan F, Bowman IA, Liu SV, Newkirk S, Bauml J, Doebele RC, Aisner DL, Gao D, Ren S, Camidge DR. ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events. J Thorac Oncol. 2019 Apr;14(4):596-605. PubMed PMID: 30543838
• Hararah MK, Stokes WA, Oweida A, Patil T, Amini A, Goddard J, Bowles DW, Karam SD. Epidemiology and treatment trends for primary tracheal squamous cell carcinoma. Laryngoscope. 2020 Feb;130(2):405-412. PubMed PMID: 30977524
• Patil T, Nie Y, Aisner DL, Camidge DR. Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology. Front Oncol. 2021;11:788245. PubMed PMID: 35070994
• Peters TL, Patil T, Le AT, Davies KD, Brzeskiewicz PM, Nijmeh H, Bao L, Camidge DR, Aisner DL, Doebele RC. Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC. NPJ Precis Oncol. 2021 Oct 12;5(1):91. PubMed PMID: 34642436
• Choudhury NJ, Schneider JL, Patil T, Zhu VW, Goldman DA, Yang SR, Falcon CJ, Do A, Nie Y, Plodkowski AJ, Chaft JE, Digumarthy SR, Rekhtman N, Arcila ME, Iasonos A, Ou SI, Lin JJ, Drilon A. Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1 -Rearranged Lung Cancers. JTO Clin Res Rep. 2021 Jul;2(7):100187. PubMed PMID: 34590036
• Thomas NJ, Myall NJ, Sun F, Patil T, Mushtaq R, Yu C, Sinha S, Pollom EL, Nagpal S, Camidge DR, Rusthoven CG, Braunstein SE, Wakelee HA, McCoach CE. Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation. J Thorac Oncol. 2022 Jan;17(1):116-129. PubMed PMID: 34455066
• Gurule NJ, McCoach CE, Hinz TK, Merrick DT, Van Bokhoven A, Kim J, Patil T, Calhoun J, Nemenoff RA, Tan AC, Doebele RC, Heasley LE. A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer. NPJ Precis Oncol. 2021 May 17;5(1):41. PubMed PMID: 34001994
• Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, Johnson ML, Heist RS, Patil T, Riely GJ, Jacobson JO, Yang X, Persky NS, Root DE, Lowder KE, Feng H, Zhang SS, Haigis KM, Hung YP, Sholl LM, Wolpin BM, Wiese J, Christiansen J, Lee J, Schrock AB, Lim LP, Garg K, Li M, Engstrom LD, Waters L, Lawson JD, Olson P, Lito P, Ou SI, Christensen JG, Jänne PA, Aguirre AJ. Acquired Resistance to KRAS(G12C) Inhibition in Cancer. N Engl J Med. 2021 Jun 24;384(25):2382-2393. PubMed PMID: 34161704
• Tsui DCC, Kavanagh BD, Honce JM, Rossi C, Patil T, Camidge DR. Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib. Clin Lung Cancer. 2022 Jan;23(1):e5-e8. PubMed PMID: 34246540
• Schenk EL, Patil T, Pacheco J, Bunn PA Jr. 2020 Innovation-Based Optimism for Lung Cancer Outcomes. Oncologist. 2021 Mar;26(3):e454-e472. PubMed PMID: 33179378
• Patil T, Simons E, Mushtaq R, Pacheco JM, Doebele RC, Bowles DW. Targeted therapies for ROS1-rearranged non-small cell lung cancer. Drugs Today (Barc). 2019 Oct;55(10):641-652. PubMed PMID: 31720561
• Patil T, Bernard B. Complications of Androgen Deprivation Therapy in Men With Prostate Cancer. Oncology (Williston Park). 2018 Sep 15;32(9):470-4, CV3. PubMed PMID: 30248169
• Sakamoto M, Patil T. Exceptional response to lorlatinib and cabozantinib in ROS1-rearranged NSCLC with acquired F2004V and L2086F resistance. NPJ Precis Oncol. 2023 Jun 8;7(1):56. PubMed PMID: 37291202
• Sakamoto M, Patil T. MET alterations in advanced non-small cell lung cancer. Lung Cancer. 2023 Apr;178:254-268. PubMed PMID: 36924573
• Langston J, Patil T, Ross Camidge D, Bunn PA, Schenk EL, Pacheco JM, Jurica J, Waxweiler TV, Kavanagh BD, Rusthoven CG. CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer. Lung Cancer. 2023 Apr;178:103-107. PubMed PMID: 36809719
• Kleczko EK, Hinz TK, Nguyen TT, Gurule NJ, Navarro A, Le AT, Johnson AM, Kwak J, Polhac DI, Clambey ET, Weiser-Evans M, Merrick DT, Yang MC, Patil T, Schenk EL, Heasley LE, Nemenoff RA. Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity. NPJ Precis Oncol. 2023 Feb 4;7(1):15. PubMed PMID: 36739466
• Iams WT, Balbach ML, Phillips S, Sacher A, Bestvina C, Velcheti V, Wang X, Marmarelis ME, Sethakorn N, Leal T, Sackstein PE, Kim C, Robinson MA, Mehta K, Hsu R, Nieva J, Patil T, Camidge DR. A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer. Clin Lung Cancer. 2023 May;24(3):228-234. PubMed PMID: 36841727
• Kummar S, Shen L, Hong DS, McDermott R, Keedy VL, Casanova M, Demetri GD, Dowlati A, Melcón SG, Lassen UN, Leyvraz S, Liu T, Moreno V, Patel J, Patil T, Mallick AB, Sousa N, Tahara M, Ziegler DS, Norenberg R, Arvis P, Brega N, Drilon A, Tan DSW. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas. Cancer. 2023 Dec 1;129(23):3772-3782. PubMed PMID: 37769113
• Patil T, Staley A, Nie Y, Sakamoto M, Stalker M, Jurica JM, Koehler K, Cass A, Kuykendall H, Schmitt E, Filar E, Reventaite E, Davis KD, Nijmeh N, Haag M, Yoder BA, Bunn PA, Schenk EL, Aisner DL, Iams WT, Marmarelis ME, Camidge DR. The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC. JTO Clin Res Rep. 2024; 5(2):100637 [Epub – doi: 10.1016/j.jtocrr.2024.100637]. PMID 38361741
• Bang TJ, Hu J, Patil T, Barón AE, Gao D, Yang JC, Kuo HY, Huang HC, Sachs PB, Camidge DR. The Effect of Intrathoracic Lesion Location on Initial Tyrosine Kinase Inhibitor Response in Advanced Oncogene-Addicted Non-Small Cell Lung Cancer: A Comparison Between RECIST 1.1 and a Novel Method of Response Assessment (MAX). Clin Lung Cancer. 2022 Dec;23(8):e501-e509. PubMed PMID: 36100512
• Simons EA, Patil T, Camidge DR. Pregnancy and Pathways to Motherhood in Oncogene-driven Lung Cancer: A Single Institution Experience. Clin Lung Cancer. 2022 Nov 11. [Epub ahead of print] PubMed PMID: 36470760
• Patil T, Bunn PA. Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions?. Clin Cancer Res. 2022 Jun 1;28(11):2204-2205. PubMed PMID: 35320359

Professional Memberships

• American Society of Clinical Oncology (ASCO), Member
• American Association of Cancer Research (AACR), Member
• International Association for the Study of Lung Cancer (IASLC), Member
• National Comprehensive Cancer Network (NCCN), Voting Member
• European Society for Clinical Oncology (ESMO), Member
• Rocky Mountain Oncology Society, President
• SWOG Cancer Research Network, Lung Steering Committee

Practice Locations

• University of Colorado Hospital

• University of Colorado Cancer Center

Specialty Information

• Internal Medicine, Board Certification (2016)
• Hematology and Oncology, Board Certification (2020)

• Cancers - Lung Cancer
• Cancers
• Cancers - Cancer Medicine